Acute Lymphoblastic Leukemia: Pharmacogenomic Insights - June 1, 2015

Genomics|Features|Optogenetics

Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia: Pharmacogenomic Insights - June 1, 2015

The pharmacogenomics of Vincristine-induced neuropathy: On pins and needles
Berg SL et al. JAMA Oncology, May 29, 2015

Pharmacogenetics predictive of response and toxicity in acute lymphoblastic leukemia therapy.
Mei L et al. Blood Rev. 2015 Jan 10.

Genomic and pharmacogenetic studies of childhood acute lymphoblastic leukemia.
Pui Ching-Hon et al. Front Med 2015 Mar (1) 1-9

Thiopurine dose intensity and treatment outcome in childhood lymphoblastic leukaemia: the influence of thiopurine methyltransferase pharmacogenetics.
Lennard L et al. Br. J. Haematol. 2015 Apr (2) 228-40

Pharmacogenetics of childhood acute lymphoblastic leukemia.
Lopez-Lopez E et al. Pharmacogenomics 2014 Jul (10) 1383-98

Comparative pharmacogenetic analysis of risk polymorphisms in Caucasian and Vietnamese children with acute lymphoblastic leukemia: prediction of therapeutic outcome?
Hoang Phuong TV et al. Br J Clin Pharmacol 2015 Mar (3) 429-40

Pharmacogenetic considerations for acute lymphoblastic leukemia therapies.
Dulucq S et al. Expert Opin Drug Metab Toxicol 2014 May (5) 699-719

Pharmacogenetics of microRNAs and microRNAs biogenesis machinery in pediatric acute lymphoblastic leukemia.
López-López E et al. PLoS ONE 2014 (3) e91261

Pharmacogenetics of methotrexate in acute lymphoblastic leukaemia: why still at the bench level?
Kodidela S et al. Eur. J. Clin. Pharmacol. 2014 Mar (3) 253-60

Pharmacogenetics of childhood acute lymphoblastic leukemia, by E Lopez-Lopez et al, Medscape, 2014